121 related articles for article (PubMed ID: 7015645)
1. A new CMF regimen.
Demicheli R; Fossati V; Garusi GF
Tumori; 1980 Dec; 66(6):743-8. PubMed ID: 7015645
[TBL] [Abstract][Full Text] [Related]
2. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
3. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
[TBL] [Abstract][Full Text] [Related]
4. Cyclic combination chemotherapy for metastatic breast cancer: comparison of two CMF schedules.
Biran S; Brufman G
Oncology; 1981; 38(5):257-9. PubMed ID: 7022295
[TBL] [Abstract][Full Text] [Related]
5. Multimodal therapy from stage-II breast cancer.
Edelstyn GA; Bates T; Brinkley D; Kitchen G; MacRae KD; Nicol NT; Spittle M; Wheeler T
Lancet; 1978 Nov; 2(8099):1092. PubMed ID: 82102
[No Abstract] [Full Text] [Related]
6. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.
Goldhirsch A; Coates AS; Colleoni M; Castiglione-Gertsch M; Gelber RD
J Clin Oncol; 1998 Apr; 16(4):1358-62. PubMed ID: 9552037
[TBL] [Abstract][Full Text] [Related]
10. High-dose versus low-dose CMFP regimen in advanced breast cancer.
Kumar A; Khanna NN; Pant GC; Khanna S
J Surg Oncol; 1984 Apr; 25(4):300-2. PubMed ID: 6371385
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
13. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
15. Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer.
Chang JC; Wergowske G
Cancer; 1981 Dec; 48(11):2503-6. PubMed ID: 7296498
[TBL] [Abstract][Full Text] [Related]
16. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
[TBL] [Abstract][Full Text] [Related]
17. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
Salimtschik M; Snel S; Havsteen H; Dombernowsky P; Mouridsen HT
Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
Boccardo F; Amadori D; Guglielmini P; Sismondi P; Farris A; Agostara B; Gambi A; Catalano G; Faedi M; Rubagotti A
Oncology; 2010; 78(3-4):274-81. PubMed ID: 20530973
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.
Brincker H; Mouridsen HT; Andersen KW
Breast Cancer Res Treat; 1983; 3(1):91-5. PubMed ID: 6347278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
